Abstract
New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Current Cancer Therapy Reviews
Title: The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Volume: 4 Issue: 3
Author(s): Kazuhito Naka, Masako Ohmura, Takayuki Hoshii, Teruyuki Muraguchi and Atsushi Hirao
Affiliation:
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Abstract: New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Export Options
About this article
Cite this article as:
Naka Kazuhito, Ohmura Masako, Hoshii Takayuki, Muraguchi Teruyuki and Hirao Atsushi, The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294267
DOI https://dx.doi.org/10.2174/157339408785294267 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Letters in Drug Design & Discovery Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents
Current Topics in Medicinal Chemistry Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued)